MiMedx Group

MiMedx Group was incorporated on February 28, 2008. Its initial assets consisted of our HydroFix® and CollaFixTM technology platforms. On January 5, 2011, the company acquired all of the outstanding equity interests in Surgical Biologics, LLC, and subsequently consolidated the corporate offices and operating facilities in Kennesaw, Georgia. This strategic acquisition brought together amnion tissue processing technology with MiMedx®'s experienced management team and extensive distribution network in order to position the company for market opportunities across multiple areas of medicine. Surgical Biologics developed allografts and other products processed from human amniotic membrane that can be used for a wide range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon protection, spine surgery, burn treatment, and many other types of procedures that require the repair of a patient’s integumental (native) tissue.
Company Growth (employees)
Type
Public
HQ
Marietta, US
Size (employees)
690 (est)
Website
mimedx.com
MiMedx Group is headquartered in Marietta, US

Key People at MiMedx Group

Parker H. Petit

Parker H. Petit

CEO & Chairman
Deborah Dean

Deborah Dean

Executive Vice President
William C. Taylor

William C. Taylor

President and Chief Operating Officer
Frank Burrows

Frank Burrows

Vice President of Corporate Strategy
Rebeccah J. C. Brown

Rebeccah J. C. Brown

Vice President of Product Development, Regulatory Affairs, and Quality Assurance

MiMedx Group Office Locations

MiMedx Group has an office in Marietta
Marietta, US (HQ)
1775 West Oak Commons Ct. NE

MiMedx Group Data and Metrics

MiMedx Group Financial Metrics

MiMedx Group's revenue was reported to be $72.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

72.6 m

Gross profit (Q1, 2017)

63.9 m

Gross profit margin (Q1, 2017), %

88%

Net income (Q1, 2017)

4.3 m

EBIT (Q1, 2017)

6.2 m

Market capitalization (17-Aug-2017)

1.9 b

Cash (31-Mar-2017)

30.9 m
MiMedx Group's current market capitalization is $1.9 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

59.2 m118.2 m187.3 m245 m

Revenue growth, %

100%58%31%

Cost of goods sold

9.3 m12.7 m20.2 m32.4 m

Gross profit

49.9 m105.6 m167.1 m212.6 m

Gross profit Margin, %

84%89%89%87%

R&D expense

12 m

General and administrative expense

180 m

Operating expense total

192 m

EBIT

(2.6 m)7.1 m24.4 m18.4 m

EBIT margin, %

(4%)6%13%8%

Interest expense

(45.2 k)(48 k)(86 k)(339 k)

Interest income

(45.2 k)(48 k)(86 k)(339 k)

Pre tax profit

(4 m)7.1 m24.3 m18.1 m

Income tax expense

(99.6 k)(832 k)5.2 m

Net Income

(4.1 m)6.2 m29.4 m12 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

25.6 m33.5 m40.8 m45.7 m49 m53.4 m57.3 m64.4 m72.6 m

Cost of goods sold

2.7 m3.3 m5.1 m5.1 m5 m7.9 m7.4 m8 m8.7 m

Gross profit

22.8 m30.2 m35.6 m40.6 m44 m45.4 m49.9 m56.4 m63.9 m

Gross profit Margin, %

89%90%87%89%90%85%87%88%88%

R&D expense

1.8 m2 m1.8 m2.1 m2.2 m2.5 m3.2 m2.9 m4.2 m

General and administrative expense

21.2 m24.2 m29.3 m32.7 m34.9 m40.6 m42.8 m48.2 m53 m

Operating expense total

23 m26.2 m31.1 m34.7 m37.1 m43.1 m45.9 m51.1 m57.2 m

EBIT

(391.8 k)3.7 m4.2 m5.7 m6.7 m1.5 m3.6 m4.7 m6.2 m

EBIT margin, %

(2%)11%10%12%14%3%6%7%9%

Interest expense

(8.4 k)(9.1 k)(14 k)1 k(5 k)(111 k)(87 k)(145 k)

Interest income

1 k(5 k)(111 k)(87 k)

Pre tax profit

(400.2 k)3.7 m4.2 m5.7 m6.7 m1.4 m3.5 m4.6 m6 m

Income tax expense

10 k(22.1 k)(146 k)(223 k)(158 k)(214 k)(1.5 m)(1.3 m)

Net Income

(390.2 k)3.7 m4.1 m5.4 m6.6 m1.2 m2 m3.3 m4.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

44.1 m46.6 m28.5 m34.4 m

Accounts Receivable

16.1 m26.7 m53.8 m67.2 m

Inventories

5.1 m1.5 m3.6 m17.8 m

Current Assets

65.4 m85.7 m96.3 m126.5 m

PP&E

4.1 m5.4 m9.5 m13.8 m

Goodwill

4 m4 m4 m20.2 m

Total Assets

84.7 m109.3 m135.9 m193.3 m

Accounts Payable

2.5 m3.7 m6.6 m11.4 m

Current Liabilities

9.6 m18.4 m26.8 m50.7 m

Total Liabilities

60.3 m

Additional Paid-in Capital

147.3 m162.4 m163.1 m161.3 m

Retained Earnings

(73.8 m)(67.6 m)(38.1 m)(26.2 m)

Total Equity

73.6 m89.3 m108 m133 m

Financial Leverage

1.2 x1.2 x1.3 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

39.2 m47.3 m38.7 m38.6 m41.1 m15.1 m23.8 m18.3 m30.9 m

Accounts Receivable

20.5 m23.3 m31 m39.4 m46.8 m53.9 m54.9 m63.4 m66.8 m

Inventories

4.2 m4.7 m4.2 m3.9 m5.7 m18 m17.2 m18.3 m16.1 m

Current Assets

66.3 m77.3 m82.3 m91.8 m102.7 m95.2 m101.8 m106.3 m121.9 m

PP&E

4.7 m5.1 m6.4 m7.2 m8.4 m12.1 m13 m13.8 m13.8 m

Goodwill

4 m4 m4 m4 m4 m30.7 m27 m27 m20.2 m

Total Assets

86 m97.3 m106.1 m113.8 m125.9 m177.2 m177.1 m181.7 m188.5 m

Accounts Payable

2.4 m2.8 m5.4 m5.6 m7.2 m13.1 m9.7 m11.2 m10.9 m

Current Liabilities

9.9 m14.4 m18.5 m19.5 m24.4 m28.8 m38.5 m41.6 m49.6 m

Additional Paid-in Capital

154.1 m157.9 m158.4 m156.4 m156.1 m151.7 m156.5 m159.9 m153.7 m

Retained Earnings

(75.1 m)(71.4 m)(63.5 m)(58.1 m)(51.5 m)(36.9 m)(35 m)(31.6 m)(21.8 m)

Total Equity

74.5 m81.3 m86.4 m93.2 m100.5 m114.2 m121.6 m123.3 m129 m

Financial Leverage

1.2 x1.2 x1.2 x1.2 x1.3 x1.6 x1.5 x1.5 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.1 m)6.2 m29.4 m12 m

Depreciation and Amortization

1.1 m928 k933 k2.1 m

Accounts Receivable

(8.4 m)(11 m)(27 m)(11.4 m)

Inventories

(858 k)(203 k)(2.3 m)(2.8 m)

Accounts Payable

1.2 m1.3 m3.1 m(3.7 m)

Cash From Operating Activities

(285.5 k)16.8 m18.8 m25.8 m

Cash From Investing Activities

(3 m)(12.2 m)(678 k)(11.7 m)

Cash From Financing Activities

40.6 m(2.1 m)(36.2 m)(8.2 m)

Income Taxes Paid

5.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(390.2 k)3.7 m4.1 m5.4 m6.6 m1.2 m2 m3.3 m4.3 m

Depreciation and Amortization

232 k232.1 k233 k233 k234 k810 k447 k631 k526 k

Accounts Receivable

20.5 m23.3 m31 m39.4 m46.8 m53.9 m54.9 m63.4 m66.8 m

Accounts Payable

2.4 m2.8 m5.4 m5.6 m7.2 m13.1 m9.7 m11.2 m10.9 m

Income Taxes Paid

7.8 m
USDY, 2017

Revenue/Employee

105.2 k

Financial Leverage

1.5 x

MiMedx Group Operating Metrics

MiMedx Group's Patent Applications was reported to be 110 in FY, 2016
FY, 2016

Patents (US)

92

Patent Applications

110

MiMedx Group Market Value History

MiMedx Group Revenue Breakdown

Traffic Overview of MiMedx Group

MiMedx Group Online and Social Media Presence

MiMedx Group Company Life and Culture

You may also be interested in